New developments in anti-HIV chemotherapy

Farmaco

Volumn 56, Issue 1-2, 2001, Pages 3-12

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

CCR5 (HIV); CXCR4 (HIV); Fusion (HIV); HIV; Integrase (HIV); Protease (HIV); Reverse transcriptase (HIV); Transcription (HIV)

Indexed keywords

4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BETULIC ACID; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DELAVIRDINE; DIDANOSINE; EMIVIRINE; EMTRICITABINE; HEPARAN; INTEGRASE INHIBITOR; LIGAND; MOZENAVIR; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSMARINIC ACID; STAVUDINE; TIPRANAVIR; TRITERPENE DERIVATIVE; UNINDEXED DRUG; VIRUS DNA; VIRUS ENVELOPE PROTEIN; ZALCITABINE; ZIDOVUDINE; ZINC FINGER PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BINDING SITE; CONFERENCE PAPER; DRUG ACTIVITY; DRUG DEVELOPMENT; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; VIRUS ADSORPTION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANTI-HIV AGENTS; HIV; HIV ENVELOPE PROTEIN GP120; HIV PROTEASE INHIBITORS; INTEGRASES; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE INHIBITORS; TRANSCRIPTION, GENETIC; ZINC FINGERS;

EID: 0035271620     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(01)01007-2     Document Type: Conference Paper

References (103)

1. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors
2. + T cells
3. Sulfated polysaccharides extracted form sea algae as potential antiviral drugs
4. A general model for the surface glycoproteins of HIV and other retroviruses
5. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry
6. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains
7. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1
8. The LD78β isoform of MIP-1α is the most potent CCR5 agonist and HIV-1-inhibiting chemokine
9. LD78β, a non-allelic variant of human MIP-1α (LD78α), has enhanced receptor interactions and potent HIV suppressive activity
10. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
11. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4
12. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection
13. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor
14. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists
15. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4
16. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event
17. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100
18. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4
19. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
20. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4
21. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry
22. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers
23. HIV-1 entry inhibitors in the side pocket
24. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection
25. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
26. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells
27. Highly conserved retroviral zinc fingers as targets for HIV-1 therapeutic management
28. SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus
29. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins
30. ADA, a potential anti-HIV drug
31. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein
32. Reverse transcription of human immunodeficiency virus type 1 is blocked by retroviral zinc finger inhibitors
33. Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins
34. Azodicarbonamide inhibits T-cell responses in vitro and in vivo
35. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections
36. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections
37. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine
38. Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants
39. In vitro anti-human immunodeficiency virus activities of Z- and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate diesters
40. In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues
41. DAPD: a novel inhibitor of HIV and HBV replication is active against drug resistant viruses, 4th International Workshop on Drug Resistance & Treatment Strategies, 12-16 June 2000, Sitges, Spain
42. Antiviral activity of 2′-deoxy-3′-oxa-4′-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice
43. Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3′-azido-2′,3′-dideoxythymidine
44. Phosphoramidate derivatives of d4T as inhibitors of HIV: the effect of amino acid variation
45. The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: a structure-activity relationship
46. Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR
47. Cyclic saligenyl phosphotriesters of 2′,3′-dideoxy-2′,3′-didehydrothymidine (d4T) - a new pro-nucleotide approach
48. ADA-bypass by lipophilic cycloSal-ddAMP pro-nucleotides. A second example of the efficiency of the cycloSal-concept
49. cycloSal-2′,3′-dideoxy-2′,3′-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system
50. cycloSal-pronucleotides of 2′,3′-dideoxyadenosine and 2′,3′-dideoxy-2′,3′-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system
51. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
52. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives
53. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1
54. 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity
55. GW420867X, a new non-nucleoside reverse transcriptase inhibitor (NNRTI) - initial phase I evaluation. Abstracts of the 12th International Conference on Antiviral Research, Jerusalem, Israel, March 21-25, 1999
56. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1
57. (-)-6-Chloro-2-[(1-furo[2,3-c]pyridin-5-yl-ethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor
58. Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus
59. Pyrido[1,2-a]indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1
60. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1
61. N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)]thio-urea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1
62. N-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-bromopyridyl)]-thiourea and N′-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1
63. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues
64. Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors
65. Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity
66. Activity of SJ-3366, a novel non-nucleoside reverse transcriptase inhibitor of HIV-1, in combination with other anti-HIV agents against wild-type and SJ-3366-resistant viral isolates, 4th International Workshop on Drug Resistance & Treatment Strategies, 12-16 June 2000, Sitges, Spain
67. HIV-1 integrase as a target for antiviral drugs
68. Highly potent synthetic polyamides, bisdistamycins, and lexitropsins as inhibitors of human immunodeficiency virus type 1 integrase
69. Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism
70. Thiazolothiazepine inhibitors of HIV-1 integrase
71. Inhibitors of HIV-1 replication that inhibit HIV integrase
72. L-Chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of zidovudine plus a protease inhibitor (AG1350)
73. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase
74. Inhibition of human immunodeficiency virus type-1 integrase by curcumin
75. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase
76. Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action
77. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase
78. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters
79. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
80. Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy
81. HIV-1 trans-activating (Tat) protein. Both a target and a tool in therapeutic approaches
82. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives
83. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives
84. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37
85. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs
86. Inhibition of HIV-1 replication by a Tat RNA-binding domain peptide analog
87. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication
88. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry
89. Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat
90. HIV protease inhibitors
91. Recent developments in HIV protease inhibitor therapy
92. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
93. Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors
94. Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors
95. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2′ structure-activity relationship, and molecular recognition of cyclic ureas
96. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450
97. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies
98. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development
99. A convergent, scalable synthesis of HIV protease inhibitor PNU-140690
100. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class
101. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor
102. Preliminary profile of the antiviral activity, metabolic effects and safety of DMP-450, a novel cyclic urea protease inhibitor, 4th International Workshop on Drug Resistance & Treatment Strategies, 12-16 June 2000, Sitges, Spain
103. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors